If AI is collapsing the cost of healthcare — are we on the brink of a historic breakthrough… or another bubble?

This week on Leading Beyond the Lab, we sit down with @Edward Kliphuis, Partner at @Sofinnova Partners, one of Europe’s leading life-sciences venture capital firms.

With over 20 years of experience spanning venture capital, digital health, tech-bio investing, and global life-sciences strategy, Edward has been at the forefront of investing where biology, computation, and healthcare collide.

In this episode, Edward covers:

- What’s genuinely different about AI in drug discovery and digital medicine today, and how collapsing healthcare costs could unlock a $10 trillion opportunity by reshaping long-term global supply–demand dynamics.

- Edward explains how @Excelsior, backed by Sofinnova Partners, @Khosla Ventures and @Deerfield Management, and led by @Mike Foley, is using an AI-driven, modular chemistry platform, originating from @Marty Burke at the @University of Illinois, to create entirely new, de novo small-molecule drugs.

- Why the US pharma & tech landscape may resemble a bubble, or a once-in-a-generation inflection point

- He talks about @Latent Labs, (led by @Simon Kohl) a Sofinnova-backed company designing entirely new proteins that do not exist in nature, unlocking new therapeutic possibilities.

- Edward outlines Sofinnova’s investment in @Bioptimus and discusses @Moon Surgical, exploring how AI and robotics are improving drug discovery and augmenting clinicians in complex procedures.

- Edward reflects on the broader AI landscape, referencing an @HSBC investment banking report questioning the long-term economics underpinning large AI models such as @OpenAI, before highlighting comments from @Geoffrey Hinton on the scalability limits of current AI architectures.

From AI-driven drug discovery and robotics in surgery, to healthcare economics, venture capital philosophy, and Europe vs the US innovation gap, this is a deep, unfiltered look at where life sciences is heading next.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Edward Kliphuis" on your preferred streaming platform, or click on the first link in the comments below!

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Youtube: https://www.youtube.com/@life_sciences

Website: https://arto-talent.com

Edward Kliphuis

Partner at Sofinnova Partners

LinkedIn: https://www.linkedin.com/in/ekliphuis/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Sofinnovas Partner's Investments

17:41 The US Pharma "Bubble" & AI

28:02 Investing in the Right CEO / Company

Hosted on Acast. See acast.com/privacy for more information.

From science fiction to clinical reality. What happens when cell therapy moves from promise to proof in patients who have run out of options?

This week on Leading Beyond the Lab, Lawrence Rose sat down with Amit Rakhit, Chief Medical Officer at BlueRock Therapeutics, to explore how regenerative medicine, leadership, and culture intersect at the most pivotal stages of biotech development.

A physician by training, Amit has built his career across large pharma and early stage biotech, including experience at Bristol Myers Squibb and Biogen, working on programmes ranging from rare disease to neurodegeneration. He is also a visible advocate for authenticity and inclusion within the life sciences industry.

In this episode, Amit covers:

• How BlueRock Therapeutics is translating the promise of cell therapy into real clinical trials for Parkinson’s disease, and why this moment is so significant for patients who have exhausted existing treatments (01:09)

• What it takes to balance bold scientific vision with realism, credibility, and execution when leading clinical programmes at a pivotal stage (03:29)

• The real differences between CEO and CMO roles, why leadership is not about hierarchy, and how self-awareness shapes long-term career impact (04:58)

• Why authenticity, diversity of thought, and culture consistently separate successful biotechs from those that struggle, more than metrics alone (06:37)

• Lessons from a career spanning programmes such as Plavix and Spinraza at Biogen, and what physician scientists should consider when transitioning into industry roles (12:00)

If you want to understand how science, leadership, and empathy come together to shape medicines that can truly change lives, this is an episode worth your time.

Check out the full conversation and hear directly from one of the industry’s most thoughtful clinical leaders.

Follow ARTO: https://linktr.ee/arto_talent

Amit Rakhit

LinkedIn: https://www.linkedin.com/in/amit-rakhit/

Lawrence Rose

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction and background

01:09 Cell therapy and BlueRock Therapeutics’ mission

03:29 Leadership, credibility, and execution

04:58 CEO vs CMO roles in biotech

06:37 Authenticity, inclusion, and culture

09:24 What separates successful biotechs

12:00 Physician scientists transitioning into industry

18:34 Career-defining moments and resilience

22:38 The future of cell therapy and emerging modalities

24:32 AI in drug discovery and clinical development

26:26 Closing thoughts and where to connect

#LeadingBeyondTheLab #ARTOTalent #CellTherapy #BiotechLeadership #RegenerativeMedicine #LifeSciences #ClinicalDevelopment

Hosted on Acast. See acast.com/privacy for more information.

97% of our viewers don't realise they aren't followed, please double check, thank you!

What does it really take to back and build world-class biotech companies from idea to FDA approval?

This week on Leading Beyond the Lab, Lawrence Rose sat down with Jonathan Tobin, Partner at Brandon Capital, to explore what truly drives success in life-science venture capital.

With over 20 years' experience spanning biotech investment, company creation, board leadership, and early-stage venture building, Jonathan has played a key role in building and scaling biotech companies across Europe, Australia and the US.

In this episode Jonathan covers:

- How Brandon Capital was co-founded in Australia by Chris Nave and Stephen Thompson, who grew it into a globally respected life sciences VC firm spanning company creation, long-term funding, and expansion in the US and UK.

- Jonathan reflects on how Brandon Capital has helped shape the Australian biotech ecosystem over the last almost 2 decades.

- Investments like AstronauTx, AdvanCell, Myricx Bio, and the stories from the frontline, including strategic pivots, tough decisions, successful exits, and the high-conviction bets that shaped portfolio outcomes.

- Practical, investor-led advice for founders raising venture capital; covering readiness, storytelling, common mistakes, and how to stand out in competitive funding rounds.

- How CatalYm has progressed deep into the clinic, and why Brandon Capital has supported the company through multiple funding rounds.

- Jonathan’s outlook on the future of biotech, from neuroscience and radiopharmaceuticals, to overlooked white-space opportunities shaping the next innovation cycle.

Be sure to check out the full episode of Leading Beyond the Lab, and don’t forget to like, subscribe, and share with anyone building in biotech.

To listen to (or watch) the full episode, search "Leading Beyond The Lab Jonathan Tobin" on your preferred streaming platform.

Hosted on Acast. See acast.com/privacy for more information.

This episode is a masterclass in how world-class life sciences investors think about risk, conviction, and real patient impact.

This week on Leading Beyond The Lab, Lawrence Rose sat down with Nikhil Thatte, Partner at Lumira Ventures, a leading Canadian life sciences venture capital firm, with over a decade of experience backing transformative biotech and medtech companies across North America.

In this conversation, Nikhil shares how Lumira Ventures has built a top-quartile VC track record over multiple market cycles, investing across therapeutic areas including oncology, gene editing, gene therapy, immunology, cardiometabolic disease, and medical devices. He also reflects on his journey helping scale globally impactful healthcare companies while staying grounded in patient outcomes.

In this episode, Nikhil covers:

• How Lumira Ventures evaluates investment opportunities in today’s biotech market, including why clinical data, valuation discipline, and a clear path to liquidity now matter more than ever (08:38)

• Lessons from Lumira’s major exit successes, including Histosonics and Endotronix, and what made these companies stand out from an investor perspective, with insights into leadership, timing, and execution alongside Mike Blue at Histosonics (02:33)

• What truly differentiates exceptional founders and management teams, with real examples of conviction moments backing leaders such as Joanna Stanicka at Axonis and Jade Doucet-Martineau at Puzzle Med (22:08)

• Why Canada punches above its weight in life sciences innovation, the structural challenges holding the ecosystem back, and what must change to retain value domestically, including reflections on Canadian success stories discussed throughout the episode (17:40)

• The vision behind the Cancer Breakthrough Fund, Lumira’s partnership with the Terry Fox Foundation, and how this model brings new capital, clinical expertise, and impact-driven investors into oncology innovation (31:08)

If you want a rare, honest look inside how top life sciences VCs assess opportunity, leadership, and long-term value creation, this is an episode you don’t want to miss.

Follow ARTO: https://linktr.ee/arto_talent

Nikhil Thatte

LinkedIn: https://www.linkedin.com/in/nikhil-thatte-72372333/

Lawrence Rose

Director at ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 Introduction to Nikhil Thatte and Lumira Ventures

02:33 Major exits including Histosonics and Endotronix

05:30 Fund V and what drives LP conviction today

08:38 How Lumira evaluates deals in the current biotech market

17:40 Canada’s competitive advantages and ecosystem challenges

22:08 Backing exceptional founders and leadership teams

31:08 The Cancer Breakthrough Fund and Terry Fox Foundation partnership

37:00 Technologies and trends shaping the next 5–10 years

41:16 Patient impact and what ultimately motivates long-term investing

#LeadingBeyondTheLab #ARTOTalent #LifeSciences #BiotechVC #Medtech #VentureCapital #CanadianInnovation

Hosted on Acast. See acast.com/privacy for more information.

Cardio-metabolic diseases are the world’s biggest killer. But what if the next generation of treatments could change everything?

This week on Leading Beyond The Lab, Lawrence Rose sat down with Jyothis George, CMO of Nodthera, and a global thought leader in the obesity space, shaping the future of cardio-metabolic and inflammatory disease innovation. Jyothis has led global programs across GLP-1, SGLT2, PCSK9 and now the emerging NLRP3 inhibitor class. His work spans companies such as Novo Nordisk, Amgen, Boehringer Ingelheim and his move into biotech with NodThera marks a shift from big-Pharma leadership into next-wave therapeutic development.

In this episode, Jyothis covers:

- How NodThera is shaping the future of metabolic and inflammatory disease treatment.

- A look at the mindset and challenges behind leading in a high-stakes biotech environment.

- Why the right investors often play a critical mentorship role in biotech growth.

- Exploring why endocrinology remains underfunded and overlooked in biotech circles.

- How he previously worked with Eli Lilly (led by David Ricks), contributing to their efforts in the cardiometabolic space.

- Reflections on personal legacy, long-term impact, and how to get in touch.

If you’re interested in cardio-metabolic innovation, GLP-1 evolution, biotech strategy or leadership at the cutting edge of science, this episode is worth your time.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Jyothis George

CMO at NodThera

LinkedIn: https://www.linkedin.com/in/jyothisgeorge/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

01:40 NodThera's Role in Future Endocrinology

10:48 Leadership in Biotech

21:05 Investment and Mentorship

30:58 Endocrinology's Underinvestment

38:13 Jyothis George: Legacy & Contact

Hosted on Acast. See acast.com/privacy for more information.

25 years of life sciences venture experience in one episode.

This week on Leading Beyond The Lab, @Lawrence Rose sat down with @Joey Mason, a venture investor with 25 years of experience across venture debt, venture capital and company building. Joey’s background spans senior roles with @Claret Capital Partners, @Sofinnova Partners, and earlier positions in investment banking and CRO services. His track record includes multiple successful exits, advising boards, working across Medtech, Biotech, digital health and Techbio, and supporting companies through regulatory approval, clinical development and commercial scale.

In this episode, Joey covers:

• Joey dives into his career spanning 25 years of Life Sciences experience, from early biotech to leading global investment firms.
• He unpacks the frameworks and philosophies that guide his investment decisions across the Life Sciences ecosystem.
• Joey reflects on a standout investment, what made it succeed, and the lessons it offers future founders.
• A candid discussion on what strong leadership looks like in high-growth Life Sciences ventures.
• Joey shares exactly what he looks for in a pitch, and what turns him off instantly.
• Looking ahead, Joey reveals where he’s placing bets and what excites him most about the next wave of Life Sciences innovation.

Check out this episode if you want a grounded, practical understanding of how life sciences companies are assessed, funded and supported behind the scenes, and how founders can communicate, hire and plan more effectively on the path to scale.

Follow ARTO!

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Lawrence Rose

Co-Founder + Talent Solutions Director at @ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Joey Mason

Venture Advisor @Sofinnova

Venture Partner @Claret Capital Partners

LinkedIn: https://www.linkedin.com/in/joey-mason/

Timestamps

01:09 Joey’s Career

05:14 Investment approaches

19:17 Most successful investment

28:20 Leadership

32:46 How to pitch to Joey Mason

42:21 Future plans

#LeadingBeyondTheLab #ARTOTalent #LifeSciences #VentureCapital #VentureDebt #Medtech #Biotech #TechBio #DigitalHealth #IrelandEcosystem #Pharma #InvestmentStrategy

Hosted on Acast. See acast.com/privacy for more information.

🤔 What does it really take to build a biotech that survives the clinical gauntlet and scales into a global business?

🎬 This week on Leading Beyond The Lab, Lawrence Rose sat down with Roel Bulthuis, Managing Partner and Head of Investments at Syncona Limited.

Roel has spent his career building, funding and scaling European biotech companies end-to-end, supporting high-performing teams from inception through clinical development, commercial launch and manufacturing scale-up.

Along the way he references outcomes from portfolio companies such as Autolus Therapeutics and Beacon Therapeutics, showing how patient capital and conviction-led strategy compound over time.

⭐️ Syncona has an impressive portfolio including,

Autolus Therapeutics, Beacon Therapeutics, Spur Therapeutics, iOnctura, Quell Therapeutics, ANAVEON AG, MOSAIC THERAPEUTIC SERVICES, Resolution Therapeutics, Purespring Therapeutics, Forcefield Therapeutics, OMass Therapeutics, Kesmalea Therapeutics, Yellowstone Biosciences, Slingshot Therapeutics.

🚀 In this episode, Roel dives into:

- What defines a Syncona company and its unique model

- Key lessons learned from both successes and setbacks

- How to manage investor involvement without stifling progress

- The challenges of leadership transitions within portfolio companies

- Syncona’s strategic commitment to the European market

- What drives Roel personally and what he enjoys most about his role

Check out this episode if you want grounded insight into biotech venture building, long-term capital strategy and how scientific founders scale from the lab to patient impact. 🤝

Follow ARTO!

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng

Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr

TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1

Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575

Website: https://arto-talent.com

Youtube: https://www.youtube.com/@life_sciences

Lawrence Rose

Co-Founder + Talent Solutions Director at @ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Role Bulthuis

Managing Partner @Syncona

LinkedIn: https://www.linkedin.com/in/roel-bulthuis-aa414a/

Timestamps:

01:10 What makes up a Syncona company?

11:25 What were the main lessons learnt from previous failures/successes?

15:06 Managing investor involvement & preventing counter productivity.

22:14 The issues with exchanging leadership.

31:07 Commitment to the European Market.

42:20 What Roel enjoys about his job.

Hosted on Acast. See acast.com/privacy for more information.

A once-in-a-century transformation, and the leader driving it.

This week, in one of our biggest episode of Leading Beyond the Lab yet, we sit down with Christophe Bourdon, CEO of LEO Pharma, a company valued in the multi-billion-euro range and entering one of the most defining chapters in its 100-year history.

With over 25+ years of global biopharma leadership experience, spanning pivotal roles at Amgen, Sanofi, and Orphazyme, Christophe brings a rare combination of commercial excellence, turnaround leadership, and global market insight. He also shares how senior leaders such as Murdo Gordon helped shape his approach to building high-performing, people-centric teams.

In this episode, Host of Leading Beyond The Lab, @Lawrence Rose, discusses with Christophe how he’s reshaping a century-old European company into a modern, innovation-driven global leader, covering:

1. Transforming LEO Pharma, from financial urgency to sustainable growth, cultural renewal, and long-term clarity.
2. The Partner and Development model, and why global players like Gilead Sciences and Boehringer Ingelheim have chosen LEO as a trusted innovation partner.
3. Leadership and culture at scale, transparency, conviction, rebuilding confidence, and empowering bold talent.
4. Preparing for a future IPO, aligning profitability, growth, and a clear 5-year vision for employees, shareholders, and partners.
5. Europe vs. the US in the next decade of biotech, why the US has become LEO’s largest affiliate and what this shift means for global competitiveness.

This episode is a rare look at what it truly takes to modernise a legacy company while keeping innovation, collaboration, and leadership at the core.

Be sure to check out this episode - one of our most important conversations to date.

Follow ARTO

LinkedIn: https://www.linkedin.com/company/artotalent

Spotify: Leading Beyond The Lab

Instagram: Instagram (@arto.talent)

TikTok: artotalent on TikTok

Apple Podcasts: Leading Beyond The Lab

Website: Home

Youtube: ARTO Recruitment

Christophe Bourdon

CEO of LEO Pharma

LinkedIn: https://www.linkedin.com/in/christophe-bourdon-77a62b6/

Lawrence Rose

Co-Founder + Talent Solutions Director At ARTO

LinkedIn: https://www.linkedin.com/in/lawrencerose/

Timestamps:

00:00 LEO’S Recent Achievements

06:58 Shaping a Modern LEO Pharma

16:30 LEO Pharma’s IPO Journey

25:39 Christophe’s Leadership

Hosted on Acast. See acast.com/privacy for more information.